Multiparametric Material Functionality of Microtissue‐Based In Vitro Models as Alternatives to Animal Testing

Stengelin, Elena; Thiele, Julian; Seiffert, Sebastian

doi:10.1002/advs.202105319

Cited by 7 publications

(5 citation statements)

References 233 publications

(413 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These elements may have a sizable effect on the biochemical milieu that underlies cell and tissue function. Bio-surfaces such as membranes are often used to better simulate the modeled organ/tissue ( Zhou et al, 2020a ; Sasserath et al, 2020 ; Ferreira et al, 2021 ; Silvani et al, 2021 ; Stengelin et al, 2022 ). Additionally, they are employed for monitoring significant physicochemical variables and simulating in-vivo conditions.…”

Section: Design and Materialsmentioning

confidence: 99%

Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

et al. 2023

View full text Add to dashboard Cite

The inefficiency of existing animal models to precisely predict human pharmacological effects is the root reason for drug development failure. Microphysiological system/organ-on-a-chip technology (organ-on-a-chip platform) is a microfluidic device cultured with human living cells under specific organ shear stress which can faithfully replicate human organ-body level pathophysiology. This emerging organ-on-chip platform can be a remarkable alternative for animal models with a broad range of purposes in drug testing and precision medicine. Here, we review the parameters employed in using organ on chip platform as a plot mimic diseases, genetic disorders, drug toxicity effects in different organs, biomarker identification, and drug discoveries. Additionally, we address the current challenges of the organ-on-chip platform that should be overcome to be accepted by drug regulatory agencies and pharmaceutical industries. Moreover, we highlight the future direction of the organ-on-chip platform parameters for enhancing and accelerating drug discoveries and personalized medicine.

show abstract

Section: Design and Materialsmentioning

confidence: 99%

Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In the relevant research of degenerative orthopedic diseases, hydrogel 3D scaffolds are mainly used. Hydrogels are cross-linked three-dimensional polymer networks that play an important role in tissue regeneration applications (Grundke et al, 2015;Eelkema and Pich, 2020;Stengelin et al, 2022). In recent years, there have been many studies on EVs loaded by hydrogels.…”

Section: D Scaffold-based Controlled Releasementioning

confidence: 99%

“…In recent years, there have been many studies on EVs loaded by hydrogels. Hydrogels with excellent properties can help EVs achieve slow release and targeted delivery and promote EV production when loading donor cells (Grundke et al, 2015;Eelkema and Pich, 2020;Ju et al, 2022;Stengelin et al, 2022;Looij et al, 2023). However, due to the characteristics of the disease model, the hydrogel-loaded EV release system has been studied more in the fields of skin injury, spinal cord injury and degenerative orthopedic diseases, but less in the fields of tumor and circulatory system diseases (Silva et al, 2018;Luo et al, 2021;Zhiwei et al, 2021;Fan et al, 2022;You et al, 2022).…”

Section: D Scaffold-based Controlled Releasementioning

confidence: 99%

Engineered extracellular vesicles as therapeutics of degenerative orthopedic diseases

Wei

Tong

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Degenerative orthopedic diseases, as a global public health problem, have made serious negative impact on patients’ quality of life and socio-economic burden. Traditional treatments, including chemical drugs and surgical treatments, have obvious side effects and unsatisfactory efficacy. Therefore, biological therapy has become the focus of researches on degenerative orthopedic diseases. Extracellular vesicles (EVs), with superior properties of immunoregulatory, growth support, and drug delivery capabilities, have emerged as a new cell-free strategy for the treatment of many diseases, including degenerative orthopedic diseases. An increasing number of studies have shown that EVs can be engineered through cargo loading, surface modification, and chemical synthesis to improve efficiency, specificity, and safety. Herein, a comprehensive overview of recent advances in engineering strategies and applications of engineered EVs as well as related researches in degenerative orthopedic diseases, including osteoarthritis (OA), osteoporosis (OP), intervertebral disc degeneration (IDD) and osteonecrosis of the femoral head (ONFH), is provided. In addition, we analyze the potential and challenges of applying engineered EVs to clinical practice.

show abstract

“…[26,27] Conversely, in the case of more complex and non-speciescomparable pathologies, it is necessary to resort to more contrived solutions, like chimeric animals. [28][29][30] To add new possibilities, in Europe, the EURL-EVCAM database on alternatives to animal experimentation provides updated information regarding the available in vitro models that represent a validated alternative to animal experimentation. In this context, validated in vitro alternatives for the assessment of drug-induced hepatotoxicity are listed in Table 1.…”

Section: The Role Of Models In Preclinical Trialsmentioning

confidence: 99%

Toward 3D‐Bioprinted Models of the Liver to Boost Drug Development

Guagliano

Volpini

Briatico‐Vangosa

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

The main problems in drug development are connected to enormous costs related to the paltry success rate. The current situation empowered the development of high-throughput and reliable instruments, in addition to the current golden standards, able to predict the failures in the early preclinical phase. Being hepatotoxicity responsible for the failure of 30% of clinical trials, and the 21% of withdrawal of marketed drugs, the development of complex in vitro models (CIVMs) of liver is currently one of the hottest topics in the field. Among the different fabrication techniques, 3D-bioprinting is emerging as a powerful ally for their production, allowing the manufacture of three-dimensional constructs characterized by computer-controlled and customized geometry, and inter-batches reproducibility. Thanks to these, it is possible to rapidly produce tailored cell-laden constructs, to be cultured within static and dynamic systems, thus reaching a further degree of personalization when designing in vitro models. This review highlights and prioritizes the most recent advances related to the development of CIVMs of the hepatic environment to be specifically applied to pharmaceutical research, with a special focus on 3D-bioprinting, since the liver is primarily involved in the metabolism of drugs.

show abstract

Multiparametric Material Functionality of Microtissue‐Based In Vitro Models as Alternatives to Animal Testing

Cited by 7 publications

References 233 publications

Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

Engineered extracellular vesicles as therapeutics of degenerative orthopedic diseases

Toward 3D‐Bioprinted Models of the Liver to Boost Drug Development

Contact Info

Product

Resources

About